GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (STU:EU6) » Definitions » Shares Outstanding (EOP)

PDS Biotechnology (STU:EU6) Shares Outstanding (EOP) : 36.68 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is PDS Biotechnology Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. PDS Biotechnology's shares outstanding for the quarter that ended in Mar. 2024 was 36.68 Mil.

PDS Biotechnology's quarterly shares outstanding increased from Dec. 2023 (33.09 Mil) to Mar. 2024 (36.68 Mil). It means PDS Biotechnology issued new shares from Dec. 2023 to Mar. 2024 .

PDS Biotechnology's annual shares outstanding increased from Dec. 2022 (30.17 Mil) to Dec. 2023 (33.09 Mil). It means PDS Biotechnology issued new shares from Dec. 2022 to Dec. 2023 .


PDS Biotechnology Shares Outstanding (EOP) Historical Data

The historical data trend for PDS Biotechnology's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology Shares Outstanding (EOP) Chart

PDS Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.28 22.26 28.45 30.17 33.09

PDS Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.72 30.87 31.01 33.09 36.68

Competitive Comparison of PDS Biotechnology's Shares Outstanding (EOP)

For the Biotechnology subindustry, PDS Biotechnology's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDS Biotechnology's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's Shares Outstanding (EOP) falls into.



PDS Biotechnology Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


PDS Biotechnology  (STU:EU6) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


PDS Biotechnology Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


PDS Biotechnology (STU:EU6) Business Description

Traded in Other Exchanges
Address
25B Vreeland Road, Suite 300, Florham Park, NJ, USA, 07932
PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

PDS Biotechnology (STU:EU6) Headlines

No Headlines